‘Radiation-induced Esophagitis Market Insights, Epidemiology, and Market Forecast-2030’ report, delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the market trends of radiation-induced esophagitis (RIE) in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
New York, Aug. 26, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Radiation Induced Esophagitis Market Insights, Epidemiology, and Market Forecast-2030" - https://www.reportlinker.com/p05932725/?utm_source=GNW
The radiation-induced esophagitis (RIE) market report provides analysis regarding current treatment practices, emerging drugs like GC4419, potential therapies, market share of the individual therapies, and historical, current and forecasted RIE market size from 2017 to 2030, segmented by seven major markets.
The report also covers current radiation-induced esophagitis treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.
• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
Study Period: 2017–2030
Radiation-induced Esophagitis – Disease Understanding and Treatment Algorithm
Radiation-induced esophagitis is a dose-limiting complication of thoracic external beam radiation. The risk of developing esophageal toxic effects depends on the radiation dose, radiation delivery method, and administration of chemotherapy. It rarely occurs in patients exposed to 30 Gy or less of radiation as per available literature.
Radiation therapy leads to mucosal damage, production of pro-inflammatory cytokines, and eventually cell death which leads to ulcerations of the esophageal mucosal lining. Radiation therapy causes cell DNA damage, leading to stress-related, pro-inflammatory cytokine production through various signaling pathways and ultimately causing mucosal damage and irritation. If severe, ulcerations of the mucosal wall can occur. Symptoms occur acutely, generally within the first 2 months. Patients typically present with nonspecific symptoms such as dysphagia and odynophagia.
This chapter covers the details of conventional and current medical therapies available for the treatment of radiation-induced esophagitis. It also provides the country-wise RIE treatment guidelines across the United States, Europe and Japan.
radiation-induced esophagitis market report gives a thorough understanding of the disease by including details such as disease definition, symptoms, types, grading, pathophysiology, and diagnosis. It also provides RIE treatment algorithms and treatment guidelines in the US, Europe, and Japan.
The radiation-induced esophagitis (RIE) epidemiology chapters provide insights about historical and current RIE patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. RIE epidemiology is segmented by the incidence of lung cancer by types, the stage-wise incidence of NSCLC, cases receiving CCRT/CRT, acute radiation-induced esophagitis (ARIE) by grade. Besides, the report includes a thorough analysis of all segments.
Radiation-induced esophagitis can be divided into two subtypes using a grading system are namely: acute and late. In the US, the cases of RIE were found to be 7,834 for grade 4, 926 for grade1, 8,508 for grade 2, 2,463 for grade 3, and 226 for grade 4, in 2017.
According to the report’s, the total prevalent population of RIE in seven major markets was 57,455 in 2017. These cases are expected to increase with a significant CAGR during the study period (2017–2030).
Among all the seven major markets, the United States accounted for the highest number of radiation-induced esophagitis cases.
This segment encloses the detailed analysis of the drugs in the radiation-induced esophagitis (RIE) pipeline. It also helps to understand the RIE clinical trial details, expressive pharmacological action, agreements of the included drug, and the latest news and press releases.
Treatment is supportive care with adequate hydration and nutrition intake. Amifostine, an organic triphosphate, has been studied and shown to act as a radioprotector. Dietary modifications are also suggested. Moreover, Galera Therapeutics’ GC4419 is the only therapy in the pipeline.
The market size of radiation-induced esophagitis (RIE) is expected to increase at a significant CAGR during the study period (2017–2030). Among all the seven major markets, the United States accounted for the largest RIE market size. Among EU5 countries, Germany had the highest market size, with USD 3.22 million in 2017, while Spain had the smallest market size of RIE, with USD 1.89 million in 2017.
This section focuses on the rate of uptake of the potential drugs in the radiation-induced esophagitis (RIE) market or expected to get launched in the market during the study period 2017–2030. The analysis covers RIE market uptake by drugs; patient uptake by therapies; and sale of each drug.
It helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs based on market share and size. All of which will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The dynamics of RIE market is anticipated to experience a positive shift in the coming years owing to the expected launch of GC-4419 (Galera Therapeutics).
Radiation-induced Esophagitis: Pipeline Development Activities
The report provides insights into different therapeutic candidates and also analyses the key players involved in developing targeted therapeutics.
Pipeline Development Activities:
The report covers the detailed information of collaborations, acquisition and merger, licensing, patent details, and emerging therapies, concerning radiation-induced esophagitis.
To keep up with current market trends, we take KOLs and SME’s opinion working in radiation-induced esophagitis domain through primary research to fill the data gaps and validate our secondary research. It will support the clients in assessing potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.
Competitive Intelligence Analysis
We have performed the competitive and market Intelligence analysis of the radiation-induced esophagitis Market by using various competitive intelligence tools that include SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies etc. Besides, the inclusion of the analysis entirely depends upon the data availability.
• In the coming years, radiation-induced esophagitis market scenario is not expected to alter much across the 7MM due to lack of approved treatment options and a static pipeline. Lack of adequate research and development activities funded by major pharma players is also making an impact on the overall landscape.
• Our in-depth analysis of the pipeline assets across different stages of development (Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities
Radiation-induced Esophagitis Report Insights:
• Patient Population
• Therapeutic Approaches
• Radiation-induced Esophagitis Pipeline Analysis
• Radiation-induced Esophagitis Market Size and Trends
• Market Opportunities
• Impact of upcoming Therapies
Radiation-induced Esophagitis Report Key Strengths:
• 11-years Forecast
• 7MM Coverage
• Radiation-induced Esophagitis Epidemiology Segmentation
• Key Competitors
• Highly Analyzed Market
• Drugs Uptake
Radiation-induced Esophagitis Report Assessment:
• Pipeline Product Profiles
• Key Products and Key Players
• Market Drivers and Barriers
• What was the radiation-induced esophagitis (RIE) market share (%) distribution in 2017 and how it would look like in 2030?
• What would be the radiation-induced esophagitis (RIE) total market size as well as market size by therapies across the 7MM during the forecast period (2017–2030)?
• What are the key findings pertaining to the market across 7MM and which country will have the largest radiation-induced esophagitis market size during the forecast period (2017–2030)?
• At what CAGR, the radiation-induced esophagitis (RIE) market is expected to grow in 7MM during the forecast period (2017–2030)?
• What would be the radiation-induced esophagitis market (RIE) outlook across the 7MM during the forecast period (2017–2030)?
• What would be the radiation-induced esophagitis (RIE) market growth till 2030, and what will be the resultant market Size in the year 2030?
• How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?
• What are the disease risk, burden and unmet needs of radiation-induced esophagitis (RIE)?
• What is the historical radiation-induced esophagitis (RIE) patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• What would be the forecasted patient pool of radiation-induced esophagitis (RIE) in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• What will be the growth opportunities in the 7MM concerning the patient population pertaining to radiation-induced esophagitis (RIE)?
• Out of all 7MM countries, which country would have the highest prevalent population of radiation-induced esophagitis (RIE) during the forecast period (2017–2030)?
• At what CAGR the population is expected to grow in 7MM during the forecast period (2017–2030)?
Current Treatment Scenario, Marketed Drugs and Emerging Therapies:
• What are the current options for the radiation-induced Esophagitis (RIE) treatment, along with the approved therapy?
• What are the current treatment guidelines for the treatment of radiation-induced Esophagitis (RIE) in the USA, Europe, and Japan?
• What are the radiation-induced Esophagitis (RIE) marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
• How many companies are developing therapies for the treatment of radiation-induced Esophagitis (RIE)?
• How many therapies are developed by each company for radiation-induced Esophagitis (RIE)?
• How many are emerging therapies in mid-stage, and late stage of development for radiation-induced Esophagitis (RIE) treatment?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the radiation-induced Esophagitis (RIE) therapies?
• What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for radiation-induced Esophagitis (RIE) and their status?
• What are the key designations that have been granted for the emerging therapies for radiation-induced Esophagitis (RIE)?
• What is the global historical and forecasted market of radiation-induced Esophagitis (RIE)?
Reasons to buy:
• The report will help in developing business strategies by understanding trends shaping and driving the radiation-induced Esophagitis (RIE) market
• To understand the future market competition in the radiation-induced Esophagitis (RIE) market and Insightful review of the key market drivers and barriers
• Organize sales and marketing efforts by identifying the best opportunities for radiation-induced Esophagitis (RIE) in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
• Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
• Organize sales and marketing efforts by identifying the best opportunities for radiation-induced Esophagitis (RIE) market
• To understand the future market competition in the radiation-induced Esophagitis (RIE) market
Which geography accounted for the largest radiation-induced esophagitis market size?
The United States accounted for the largest RIE market size.
What is forecasted radiation-induced esophagitis size in 2030?
estimates an increase in RIE Market Size during the study period, 2017–2030
What are the present radiation-induced esophagitis drivers?
Increasing incidence of cancers leading to more usage of radiation therapy, development of novel therapeutic approaches and scoring systems
What are the radiation-induced esophagitis market barriers?
Lack of epidemiology-based literature, Disease Rarity, Risk of Recurrence.
How many companies are developing drugs for radiation-induced esophagitis?
Currently, only one key pharma player is developing the drug for RIE.
Which are the leading companies in radiation-induced esophagitis market?
Key Player – Galera Therapeutics
How is epidemiology segmented for radiation-induced esophagitis?
Incidence of Lung Cancer by Types, Stage-wise Incidence of NSCLC, Cases receiving CCRT/CRT, Acute radiation-induced esophagitis (ARIE) by grade
Read the full report: https://www.reportlinker.com/p05932725/?utm_source=GNW
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.
CONTACT: Clare: email@example.com US: (339)-368-6001 Intl: +1 339-368-6001